CalbaTech Announces Addition of Jason Van Tassel, M.D.,
Prominent Physician/Surgeon With Significant Research
Accomplishments, to Its Scientific Advisory Board 10/25/04 08:01
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, today announced that Dr. Jason Van Tassel, who has significant experience in optimizing the manufacturing processes related to monoclonal antibody test assays, has joined the Company's Scientific Advisory Board.
Dr. Jason Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, Ca. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Dr. Van Tassel was accepted into the well-known Department of Otolaryngology, Head and Neck Surgery Residency program at the University of Arkansas for Medical Sciences, headed by world famous Dr. James Suen. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery.
Prior to beginning his practice of medicine in Los Angeles, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays, an area of specific interest to CalbaTech. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Department of Neurosciences at San Diego State under Dr. Gregory Harris, Ph.D., also an area of significant potential interest for CalbaTech.
"We are pleased that Dr. Van Tassel, an accomplished physician with expertise in fields of particular interest to CalbaTech, has agreed to join our Scientific Advisory Panel," said James DeOlden, CEO. "Dr. Van Tassel was the inventor of the Stem Cell Delivery Device, a technology that CalbaTech acquired last year, and he will work with Dr. John Drews of our Scientific Advisory Board to position this technology for license or acquisition. Dr. Van Tassel has been an important contributor to CalbaTech's future, and we know he will continue to contribute, as an advisor and inventor, to the success of our Company."
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing early stage life science based companies that are developing next generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute breakthrough innovation in areas of biological discovery.
Contact:
Paul Knopick
E&E Communications
(949) 707-5365
pknopick@eandecommunications.com
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for CalbaTech, Inc.
calbatech.com
. |
